Natrol will distribute red clover supplement at cancer fundraiser
CHATSWORTH, Calif. Natrol announced Thursday morning that it will provide 1,500 Trinovin samples for men at the eighth annual Cruisin’ For A Cure fundraiser benefiting UCLA’s Jonsson Cancer Center to support prostate cancer research that will be held Sept. 22.
Cruisin’ For A Cure is a one-day charity custom/classic auto show that features approximately 3,500 display vehicles, more than 200 vendors and exhibitors, and a 1.5-mile cruise route.
Trinovin is a natural supplement derived from red clover that helps support men’s prostate and urinary health that retails for a suggested $19.99, the company reported.
B&L, Alcon settle lawsuit over color scheme
ROCHESTER, N.Y. Bausch & Lomb and Alcon Laboratories earlier this week settled the lawsuit recently filed by B&L concerning Alcon’s promotional claims about Bausch & Lomb’s ReNu MultiPlus multi-purpose disinfecting solution.
The suit centered on Alcon’s use of a color-coded chart showing differences in superficial punctate transient corneal staining profiles observed in Dr. Gary Andrasko’s research. To address Bausch & Lomb’s concern over the red-yellow color scheme of Dr. Andrasko’s corneal staining grid, Alcon has agreed to change the red-yellow color scheme used in its promotional materials.
The use of the color scheme in Alcon’s materials was not intended to communicate that the lens-solution combinations designated red or yellow meant danger or caution, and was not meant to suggest an increased risk of corneal infection.
In light of Alcon’s and B&L’s agreements, the lawsuit has been dismissed with prejudice, without any payment of damages from either party.
Adams ranks high on Deloitte list
Adams Respiratory Therapeutics ranked No. 7 in Deloitte & Touche’s Technology Fast 50 Program for New Jersey, a ranking of the 50 fastest growing technology, media, telecommunications and life sciences companies in the area, the company announced Monday.
“We are very proud to be recognized by Deloitte for achieving a revenue growth rate of 1,638 percent from 2002 to 2006,” commented Michael Valentino, chief executive officer of Adams, on the distinction. “It has been exhilarating to see the things we’ve done take hold. Our unique regulatory strategy for Mucinex coupled with our synergistic blend of consumer and professional marketing for the Mucinex brand helped fuel our phenomenal growth over the past five years. … We now market nine over-the-counter products with multiple new product introductions planned this fall. Additionally, we also plan to expand into the prescription respiratory market as early as 2008.”